12:59 PM


Not supposed for U.S. and UK Media – Two-year topline outcomes from the pivotal gape PULSAR:


Results from PULSAR hiss very prolonged time duration efficacy of aflibercept 8 mg with prolonged dosing intervals reaching up to 24 weeks and imaginative and prescient improvements comparable to Eylea™ (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients randomized at baseline to aflibercept 8 mg 16-week dosing regimen obtained a mean of 8.2 injections (4.6 fewer than Eylea (aflibercept 2 mg)) over two years / Safety profile of aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) stays comparable to Eylea (aflibercept 2 mg) with out a original alerts identified